ADAG

Adagene, Inc. Sponsored ADR · NASDAQ

Performance

-6.38%

1W

-8.97%

1M

-21.66%

3M

+96.28%

6M

+36.69%

YTD

+81.44%

1Y

Profile

Adagene Inc., a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Technical Analysis of ADAG 2024-04-19

Overview:

In analyzing the technical indicators for ADAG stock over the last 5 days, we will delve into the trends, momentum, volatility, and volume aspects to provide a comprehensive outlook on the possible future stock price movement. By examining key indicators such as moving averages, MACD, RSI, Bollinger Bands, and OBV, we aim to offer valu...

See more ...

Recent News & Updates